CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Files An 8-K Financial Statements and Exhibits
CAPRICOR THERAPEUTICS, INC. Exhibit
EX-99.1 2 tv511315_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA FDA Provides Positive Feedback on Design for HOPE-2 Clinical Trial LOS ANGELES,…
To view the full exhibit click
About CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.